Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. Financials
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
Delayed Swiss Exchange  -  05/20 12:45:50 pm EDT
86.70 CHF   +1.18%
05/20Novartis' Cosentyx Recommended by EU Committee for Approval in Juvenile Arthritis
MT
05/20Novartis Cosentyx(R) (secukinumab) receives positive CHMP opinion for expanded use in childhood arthritic conditions
DJ
05/20Novartis Cosentyx® (secukinumab) receives positive CHMP opinion for expanded use in childhood arthritic conditions
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 214 715215 682196 476193 025--
Enterprise Value (EV)2 230 615240 182204 667200 853198 640194 624
P/E ratio 30,4x26,7x8,20x20,3x17,7x16,6x
Yield 3,19%3,56%3,83%3,74%3,88%4,00%
Capitalization / Revenue 4,53x4,43x3,81x3,65x3,53x3,45x
EV / Revenue 4,86x4,94x3,96x3,80x3,63x3,48x
EV / EBITDA 14,6x14,3x11,2x11,0x10,4x9,80x
Price to Book 3,87x3,78x2,90x3,08x3,08x2,95x
Nbr of stocks (in thousands) 2 264 6082 274 5062 237 0922 171 940--
Reference price (USD) 94,894,887,888,988,988,9
Announcement Date 01/29/202001/26/202102/02/2022---
1 CHF in Million
2 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 47 44548 65951 62652 85354 65455 910
EBITDA1 15 80916 84518 24618 19219 18119 853
Operating profit (EBIT)1 14 11215 41616 58816 98618 30619 095
Operating Margin 29,7%31,7%32,1%32,1%33,5%34,2%
Pre-Tax Profit (EBT)1 8 9409 87826 13711 47512 90413 636
Net income1 7 1478 07224 0219 32510 33810 745
Net margin 15,1%16,6%46,5%17,6%18,9%19,2%
EPS2 3,123,5510,74,395,035,36
Dividend per Share2 3,023,383,363,323,443,55
Announcement Date 01/29/202001/26/202102/02/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4
Net sales1 13 03013 22912 53112 92513 17913 665
EBITDA1 4 8714 274-4 5624 5914 752
Operating profit (EBIT)1 4 4673 8194 0834 3034 4324 164
Operating Margin 34,3%28,9%32,6%33,3%33,6%30,5%
Pre-Tax Profit (EBT) 3 23016 9512 669---
Net income1 2 75816 3082 2222 4752 6072 365
Net margin 21,2%123%17,7%19,2%19,8%17,3%
EPS2 1,237,291,001,121,171,15
Dividend per Share ------
Announcement Date 10/26/202102/02/202204/26/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 15 90024 5008 1917 8285 6151 599
Net Cash position1 ------
Leverage (Debt / EBITDA) 1,01x1,45x0,45x0,43x0,29x0,08x
Free Cash Flow1 12 87511 69113 28213 19214 62515 138
ROE (Net Profit / Equities) 17,5%23,5%22,7%20,7%22,8%23,7%
Shareholders' equity1 40 84234 376105 88544 94045 40945 289
ROA (Net Profit / Asset) 8,89%6,45%10,9%7,86%8,82%9,26%
Assets1 80 393125 215221 201118 638117 160116 097
Book Value Per Share2 24,525,130,328,928,830,2
Cash Flow per Share2 5,885,956,676,747,287,72
Capex1 2 2571 2751 3781 7401 7491 746
Capex / Sales 4,76%2,62%2,67%3,29%3,20%3,12%
Announcement Date 01/29/202001/26/202102/02/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Analysis
EQT pushes back Galderma IPO plans amid market turmoil - sources
Stock Pick
 NOVARTIS AG
Back to basics
Key data
Capitalization (CHF) 188 307 222 276
Capitalization (USD) 193 024 747 095
Net sales (USD) 51 626 000 000
Number of employees 110 000
Sales / Employee (USD) 469 327
Free-Float 88,1%
Free-Float capitalization (CHF) 165 925 977 153
Free-Float capitalization (USD) 170 082 800 805
Avg. Exchange 20 sessions (USD) 417 662 966
Average Daily Capital Traded 0,22%
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA